ReviewBiochemia medica2025
Bilirubin - new insights into an old molecule.
Review in Biochemia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Heme Oxygenase-1 in Bone Remodeling: Molecular Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- Preliminary Assessment of Red Beetroot Supplementation and Cultivar Effects in Low-Protein-Fed WKY Rats.Nutrients · 2026Article
- Retinol-guided liposomal platform for targeted pirfenidone delivery in hepatic fibrosis.Journal of nanobiotechnology · 2026Article
- A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer.Scientific reports · 2026Article
- The Impact ofGenes · 2026Article
- Plasma SERPINA3 and its clinical correlates in adolescent major depressive disorder: an exploratory case-control study.BMC psychiatry · 2026Article
- EphB4-decorated biomimetic nanoparticles enhance osteoclast targeting and therapeutic effect in osteoporosis.Journal of nanobiotechnology · 2026Article
- Preclinical evaluation of gefitinib and betulin-loaded surface functionalized liposomes for the treatment of hepatocellular carcinoma via asialoglycoprotein receptor targeting.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Microbiome-derived cancer: the catabolism of bilirubin to urobilin in the liver-gut axis and its consequences.Gastroenterology report · 2026Review
- Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For decades, bilirubin was thought to be merely a degradation product of the hem, a potentially toxic compound and a molecule with no specific physiological function. Recently, it has been discovered that bilirubin has a strong antioxidant effect and possesses molecular signalling, hormonal and immunomodulatory properties. Numerous studies show that moderately elevated serum bilirubin concentrations correlate with a lower risk of developing pathological conditions mediated by oxidative stress and inflammation. Low concentrations within the current reference interval have been shown to be a potential risk factor for various pathological conditions. It is to be expected that knowledge about bilirubin will lead to the determination of bilirubin concentration gaining new importance in diagnostics, for example as a prognostic marker, but also as a therapeutic molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.